返回 A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Hosts the Fifth Science and Technology Conference

[2017-05-16] 

Shanghai, China – On May 8, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") hosted its Fifth Science and Technology Conference in its Shanghai headquarters to share the developments of its on-going R&D projects and awarded R&D talents.
 
The meeting was chaired by Yiyun Que, First Vice President of Coronary Manufacturing and Engineering. At the beginning of the meeting, Dr. Qiyi Luo, MicroPort® Chief Technology Officer ("CTO") and Director of MicroPort® Research & Engineering Academy, delivered a speech to encourage MicroPort® R&D staff to constantly hunt for new ideas. He said, the Science and Technology Conference aims to provide a platform for R&D employees to share the R&D progress and achievements in the past year and exchange ideas regarding cutting-edge technologies to gain new inspirations. Since its launch four years ago, the Science and Technology Conference has helped to foster an atmosphere of active innovation around the company and create a sound environment for scientific innovation. In this way, it enhanced the awareness of R&D employees for innovation and aspiration, leading to numerous technological advancement and breakthroughs and improved innovative capabilities of the company, and thereby lays a great foundation for the company's future development.
 
Afterwards, 12 project teams from MicroPort® R&D Department, MicroPort® Quality Department, MicroPort® EP, MicroPort® NeuroTech, and MicroPort® CardioFlow MedTech, made presentations about the background, applications, current status and future developments of their projects. The introductions were followed by an active Q&A session which stimulated both the audience and speakers. In this year's Science and Technology Conference, a new session was added to display 50 posters about the brief introduction of research projects, which attracted wide attention and hot discussions from the attendees.
 
In the following award session, MicroPort® Chairman and Chief Executive Officer Dr. Zhaohua Chang and MicroPort® CTO Dr. Luo issued certificates of honor to 30 young talents and six project leaders. Meanwhile, several patent inventors were awarded patent certificates and a team was recognized for its outstanding achievements in obtaining patents in the year 2016. In the end of the meeting, five project presentations and 10 posters were selected as excellent presentations and posters, and the teams were awarded honor certificates respectively by Zhonghua Li, Executive Vice President of MicroPort Endovascular (Shanghai) Co., Ltd. and Dr. Chengyun Yue, First Vice President of Corporate Strategy and Planning.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:MicroPort® Endovascular Attends Sixth Northwest Vascular Forum
[Next]:FireMagic™ 3D Gains CFDA Approval